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ABSTRACT 
 
I am very pleased to write an inaugural editorial for the new journal, Diabesity as the editor-in-charge. 
Diabesity is a unique peer-reviewed open access interdisciplinary journal dedicated to publishing high-quality 
articles in the areas of physiology, pathology and therapeutic aspects of diabetes, obesity and their 
complications. Diabesity focuses on clinical and experimental pharmacology and therapeutics in any aspect of 
these metabolic ailments in various experimental and clinical settings. Current therapeutic agents for obesity and 
diabetes are inadequate as the number of cases is on the rise. Along with public health strategies, 
development of alternative therapeutic agents is anticipated. Therefore, extensive research is being conducted in 
this field and is drawing intense attention from researchers, practitioners and the general public. Here arises the 
significance of a journal like Diabesity which can serve as a platform for knowledge sharing and the promotion 
and dissemination of new scientific advancements to a wide spectrum of readers. 
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Introduction 
I am very pleased to write an inaugural 
editorial for the new journal, Diabesity as the editor-in-
charge. Diabesity is a unique peer-reviewed open access 
interdisciplinary journal dedicated to publishing high-
quality articles in the areas of physiology, pathology 
and therapeutic aspects of diabetes, obesity and their 
complications. Accordingly, Diabesity focuses on 
clinical and experimental pharmacology and 
therapeutics in any aspect of these metabolic ailments 
in various experimental and clinical settings. 
As we all know, obesity and diabetes epidemic 
poses a major health-care challenge world-wide.1,2 An 
unhealthy lifestyle (high caloric diets and lack of 
physical activity) accelerates this epidemic, when 
superimposed with genetic susceptibility.3,4 Current 
therapeutic agents for obesity and diabetes are 
inadequate as the number of cases is on the rise. Along 
with public health strategies, development of 
alternative therapeutic agents is anticipated. Therefore, 
extensive research is being conducted in this field and 
is drawing intense attention from researchers, 
practitioners and the general public. Here arises the 
significance of a journal like Diabesity which can serve 
as a platform for knowledge sharing and the 
promotion and dissemination of new scientific 
advancements to a wide spectrum of readers. 
 
Diabesity 
The term ‘diabesity’ is relatively new; and first 
emerged after the recent establishment of a strong link 
between obesity and diabetes substantiated through 
clinical evidence. As evident from recent clinical data, 
proliferation in the prevalence of obesity is closely 
paralleled by the increase in the prevalence of diabetes. 
These ailments exist as two sides of the same coin and 
the clinical and research community are trying to 
elucidate this link. The driving forces linking diabetes 
and obesity remain to be explained due in part to the 
fact that environmental, genetic, life style and 
behavioral factors are involved in the pathogenesis of 
these disease states. Therefore we believe there is 
room for a dedicated interdisciplinary journal in the 
area of diabesity despite the fact that there are many 
reputable journals which already exist in the areas of 
diabetes and obesity. 
 
Scope of Diabesity 
Diabesity publishes but is not limited to 
clinical and experimental pharmacology and 
therapeutics in any aspect of metabolic diseases, either 
in humans or animal models and in vitro systems. 
Diabesity also welcomes manuscripts on any aspect of 
physiological and pathological pancreatic islet function 
and intermediary metabolism, mechanisms of drug and 
hormone action, and biochemical and molecular 
aspects of normal and abnormal biological processes.  
In addition, articles encompassing clinical nutrition, 
adipogenesis and lipid metabolism, neuroscience, 
transgenic models, metabolic syndrome, nutrition 
behavior, pediatric obesity, and adipocyte cell biology 
are also of interest. 
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Diabesity will accept original research articles, 
review articles, editorials, case reports and short 
communications on all the aspects of diabetes, obesity 
and metabolic syndrome. The journal has an online 
submission and editorial tracking system for a rapid 
and quality review process. The review process is 
carried out through the editorial board members or 
other experts from the field with the highest standards 
of professional ethics. The editorial board for this 
journal consists of prominent scientists around the 
world including countries such as Canada, the United 
States of America, Japan, Brazil, France, India and 
China. 
 
Concluding remarks  
Again, I welcome you to the inaugural issue of 
Diabesity, and I hope that researchers and clinicians 
exploring the diabesity enigma will turn to the journal 
Diabesity as a platform for their outstanding research 
work. I hope to hear from you, through your 
submissions, reviews, or letters to the editor to express 
your views and ideas. 
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